Biofrontera Inc. (BFRI): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 08:10 ET
- Event date
- 2026-11-13
- Accession no.
- 0001493152-26-051546
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Biofrontera reports third-quarter revenue of $9.1 million and net loss of $6.4 million
Biofrontera reported third-quarter net product revenue of $9.1 million, up 29.8%, and a net loss of $6.4 million, compared to $6.6 million in the prior-year period. Gross margin was 74.4%, compared to 70.7%. The company also disclosed FDA approval of Ameluz for superficial basal cell carcinoma and a customs ruling that its redesigned RhodoLED XL-C was not subject to the ITC exclusion order.
- Third-quarter net product revenue was $9.1 million, up 29.8% from $7.0 million in the prior-year period.
- Third-quarter net loss was $6.4 million, or $(0.42) per share, versus $6.6 million, or $(0.62) per share.
- Cash and cash equivalents were $3.2 million as of September 30, 2026, compared to $6.4 million as of December 31, 2025.
- On September 14, 2026, U.S. Customs and Border Protection ruled the redesigned RhodoLED XL-C was not subject to the exclusion order.
earningsregulatory
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | form8-k.htm |
| EX-99.1 | EX-99.1 | ex99-1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.